0000000000894205

AUTHOR

Andrea Distelrath

showing 1 related works from this author

Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice: First interim analysis of the National Non-I…

2016

581Background: In 2013 a subcutaneous (SC) formulation of trastuzumab (T) was approved based on non-inferiority to intravenous (IV) T as proven in the HannaH trial. So far no data from the routine ...

OncologyCancer Researchmedicine.medical_specialtybusiness.industryInterim analysisSurgeryOncologyTrastuzumabInternal medicineNon interventionalmedicineRoutine clinical practiceskin and connective tissue diseasesbusinessmedicine.drugEarly breast cancerJournal of Clinical Oncology
researchProduct